Skip to main content

7 Result(s)

within A S Ruppert Remove this filter

and

  1. No Access

    Article

    Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic leukemia

    Chronic lymphocytic leukemia (CLL) is frequently complicated by secondary autoimmune cytopenias (AICs). Ibrutinib is an irreversible inhibitor of Bruton’s tyrosine kinase approved for the treatment of relapsed...

    K A Rogers, A S Ruppert, A Bingman, L A Andritsos, F T Awan, K A Blum… in Leukemia (2016)

  2. No Access

    Article

    miR-155 expression is associated with chemoimmunotherapy outcome and is modulated by Bruton’s tyrosine kinase inhibition with Ibrutinib

    D Guinn, A S Ruppert, K Maddocks, S Jaglowski, A Gordon, T S Lin, R Larson… in Leukemia (2015)

  3. No Access

    Article

    The hematopoietic stem cell transplant comorbidity index can predict for 30-day readmission following autologous stem cell transplant for lymphoma and multiple myeloma

    Patients who undergo autologous stem cell transplant (ASCT) for hematologic malignancies frequently have multiple comorbidities. The hematopoietic cell transplantation comorbidity index (HCT-CI), a transplant-...

    S M Jaglowski, A S Ruppert, C C Hofmeister, P Elder, W Blum… in Bone Marrow Transplantation (2014)

  4. No Access

    Article

    Impact of targeted therapy on outcome of chronic lymphocytic leukemia patients with relapsed del(17p13.1) karyotype at a single center

    D M Stephens, A S Ruppert, J A Jones, J Woyach, K Maddocks, S M Jaglowski… in Leukemia (2014)

  5. No Access

    Article

    Association of pre-transplantation positron emission tomography/computed tomography and outcome in mantle cell lymphoma

    Positron emission tomography/computed tomography (PET/CT)-positive findings before autologous SCT (auto-SCT) are associated with inferior PFS and OS in patients with relapsed Hodgkin’s and diffuse large B-cell...

    J B Cohen, N C Hall, A S Ruppert, J A Jones, P Porcu… in Bone Marrow Transplantation (2013)

  6. No Access

    Article

    Outcome of patients with relapsed or refractory chronic lymphocytic leukemia treated with flavopiridol: impact of genetic features

    J A Woyach, G Lozanski, A S Ruppert, A Lozanski, K A Blum, J A Jones, J M Flynn… in Leukemia (2012)

  7. No Access

    Article

    Risk factors for tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with the cyclin-dependent kinase inhibitor, flavopiridol

    Tumor lysis syndrome (TLS) has been described in over 40% of patients with chronic lymphocytic leukemia treated with the cyclin-dependent kinase inhibitor, flavopiridol. We conducted a retrospective analysis t...

    K A Blum, A S Ruppert, J A Woyach, J A Jones, L Andritsos, J M Flynn, B Rovin… in Leukemia (2011)